Zusammenfassung
In den letzten Jahren haben mehrere Arbeitsgruppen versucht, den Verlauf einer chronisch-aktiven Hepatitis (CAH) durch Immunstimulation und im Falle einer chronischen Hepatitis B auch durch eine antivirale Behandlung günstig zu beeinflussen. Die Anregung des Immunapparates durch das Absetzen einer immunsuppressiven Medikation wurde schon im vorausgehenden Referat von Prof. Vido besprochen. Als Immunstimulanzien wurden darüber hinaus Laevamisol, verschiedene bakterielle Antigene, Transferfaktor und informatorische RNS (I-RNS) eingesetzt. Laevamisol soll die T-Zellaktivität und die Phagozytosefähigkeit von Monozyten und Makrophagen steigern. Die Ergebnisse aller Studien, in denen diese Substanz eingesetzt wurde, stimmen darin überein, daß sich ein günstiger therapeutischer Effekt bei chronisch-aktiver Hepatitis nicht erzielen läßt (Javor et al. 1978; Piccari et al. 1979; Ponzetto et al. 1979; Fattovich et al. 1981). Die Therapie mußte bei einigen Patienten wegen Übelkeit und exanthematischen Hautausschlägen abgebrochen werden. In einem Fall wurde eine Agranulozytose beschrieben (Nilius et al. 1983).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Bassendine MF, Chadwick RG, Salmeron J, Shipton U, Thomas C, Sherlock S (1979) Treatment of HBsAg-positive chronic liver disease with adenine arabinoside. Gut 20: 906
Brechot C, Hadchonel M, Scotte J, Fonck M, Potet F, Vyas GN, Tiollais P (1981a) State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver disease. Proc Natl Acad Sci USA 78: 2906
Brechot C, Hadchonel M, Scotto J, Degos F, Charnay P, Trepo C, Tiollais P (1981b) Detection of hepatitis B virus DNA in liver and serum. Lancet II:765
Brzosko WJ, Debski R, Derecka K (1978) Immunstimulation for chronic active hepatitis. Lancet II:311
Chadwick RG, Bassendine MF, Crawford EM, Thomas HC, Sherlock S (1978) HBsAg-positive chronic liver disease: Inhibition of DNA polymerase activity by vidarabine. Br Med J II: 531
Desmyter J, DeGroote J, Demet VJ et al. (1976) Administration of human fibrobalst interferon in chronic hepatitis B infection. Lancet 1I: 645
Dolen J, Carter GWA, Horoszewicz JS, Vladutin AO, Leibowitz AI, Nolan JP (1979) Fibroblast interferon treatment of a patient with chronic active hepatitis. Am J Med 67: 127
Eisenburg J (1979) Behandlung der Virushepatitis. Bew?hrte Methoden and neue Wege. Fortschr Med 97:1363
Fattovich G, Crivellaro C, Cadrobbi P, Pornaro E, Alberti A, Realdi G (1981) Virological changes in HBsAg-positive active hepatitis in childhood during levamisole-treatment (Abstract). EASL, Lissabon
Gil J, Ziemka J, Brzosko J et al. (to be published) Immunotherapy of chronic active viral hepatitis B with propioni-bacterium granulosum. Hepatogastroenterology
Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC (1976) Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 295: 517
Javor R, Pear A, Bajtai G, Amburg M, Hollós I, Kovâvs M (1978) Immunstimulation als therapeutisches Prinzip bei der chronischen Hepatitis. Wiss Z Ernst Moritz Arndt Universität Greifswald 27: 105
Kato Y, Kobayashi K, Suyama T, Hattori N (1979) Effects of human leukocyte interferon therapy on hepatitis B virus in patients with chronic active hepatitis. Gastroenterology 77: 21
Kingham JGC, Ganguly NK, Shaari ZD et al. (1978) Treatment of HBsAg-positive chronic active hepatitis with human fibroblast interferon. Gut 19: 91
Kondo M, Matsumura N, Yoshikawa T, Nishida K, Tagami H (1980) Effect of human leukocyte interferon on hepatitis surface antigen. Hepatogastroentrology Abstracts of the XI. Internat. Congress of Gastroenterology, Hamburg, June 8–13. 1980. Thieme, Stuttgart New York, p 353
Koshy R, Kaupas P, Müller R, Hofschneider PH (1981) Detection of hepatitis B virus specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissue. J Gen Virol 57: 95
Lok ASF, Karayiannis P, Brown D, Fowler MJF, Monjardino J, Thomas HC, Sherlock S (1983) Suppression of hepatitis B virus (HBV) replication with thrice weekly lymphoblastoid interferon (Abstract W 9 ). EASL, Southampton
Müller R (1980) Neue Aspekte der Therapie von Virushepatitiden. Mitt Klin Nephrol 9: 108
Müller R, Vido I, Siegert W, Wöltje M, Klein H, Staar U, Schmidt FW (1980) Exogenous interferon in chronic hepatitis B infection. In: Bianchi L, Gerok W, Sickinger K, Stalder GA (eds) Virus and the liver. MTP Press, Lancester, p 355
Müller R, Siegert W, Hofschneider HP, Deinhardt F, Frösner G, Vido I, Schmidt FW (1981) Treatment of chronic active hepatitis B (CAHB) with human interferon-beta. In: DeMeyer E, Galazzo G, Schellekens H (eds) The biology of the interferon system. Elsevier/ North Holland, Amsterdam, p 355
Müller R, Vido I, Klein H, Wille E, Schmidt FW (1983) Human interferon-beta (HIFN-ß) and adenine arabinoside 5’-monophosphate (ARA-AMP) in HBsAg chronic active hepatitis (CAH) (Abstract W 10 ). EASL, Southampton
Nilius R, Schentke U, Otto L et al. (1983) Levamisole therapy in chronic hepatitis. Results of a multicentric double blind trial. Hepatogastroenterology 30: 90
Piccari GG, D’Imperio N, Formica G, Piemontese A, Sarti F, Spongano P, Del Monte PR (1979) Levamisole therapy in chronic active liver diseases (Abstract). EASL, Düsseldorf
Pizza G, Viza D, Roda A, Aldini E, Roda E, Barbara L (1979) Transfer factor for the treatment of chronic active heaptitis. N Engl J Med 300: 1332
Pollard RB, Smith JL, Neal EA, Gregory PB, Merigan TC, Robinson WS (1978) Effect of vidarabine on chronic hepatitis B virus infection. JAMA 239: 1648
Ponzetto A, Bonini F, Arrigoni A et al. (1979) Immunostimulant therapy in HBSAg + chronic active liver disease: A pilot controlled trial with levamisole (Abstract). EASL, Düsseldorf
Schaffner F (1980) New approaches to treatment of hepatitis B chronic liver disease. In: Bianchi L, Gerok W, Sickinger K, Stalder GA (eds) Virus and the liver. MTP Press, Lancaster, p 367
Schober A, Kaboth W, Biswas R, Gerlich W, Stamm B, Creutzfeld W (1979) Treatment of chronic hepatitic B virus (HBV-)-infection with ribavirin. 5. Internat. Congr. of liver diseases Basel, October 1979
Scullard GH, Alberti A, Wansbrough-Jones MH et al. (1979) Effects of human leukocyte interferon in hepatitis B virus replication and immuno responses in patients with chronic hepatitis B infection. J Clin Lab Immunol 1: 227
Scullard GH, Andres LL, Greenberg HB et al. (1981a) Antiviral treatment of chronic hepatitis B virus infection: Improvement in liver disease with interferon and adenine arabinoside. Hepatology 1: 228
Scullard GH, Pollard RB, Smith JL, Sacks SL, Gregory PB, Robinson WS, Merigan TC ( 1981 b) Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J Infect Dis 143: 772
Shulman S, Schulkind M, Ayoub E (1974) Transferfactor therapy of chronic active hepatitis. Lancet II:650
Smith CJ, Kitchen LW, Scullard GH, Robinson WS, Gregory PB, Merigan TC (1982 a) Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis V infection. JAMA 247:2261
Smith CJ, Scullard GH, Gregory PB, Robinson WS, Merigan TC ( 1982 b) Preliminary studies of acyclovir in chronic hepatitis B. Acyclovir Symp. Am J Med 73: 267
Sodomann CP, Maerker-Alzer G, Havemann K et al. (1979) Transfer factor treatment of patients with HBsAg positive active hepatitis. Klin Wochenschr 57: 193
Tong MJ, Nastrom JS, Redecker AG, Marshall GJ (1976) Failure of transfer factor therapy in chronic active B hepatitis. N Engl J Med 295: 209
Toshitsugu ODA (1980) Effect of human leukocyte or fibroblast interferon on hepatitis B virus infection in patients with chronic hepatitis. Conference on clinical and malignant tumors. Osio, Japan, December 2–4, 1980
Trepo C, Hantz O, Coupier D, Chossegros P, Chevallier R, Brette R (1983) Comparative tolerance and efficiacy studies of ARA-A, ARA-AMP, acyclovir and leucocyte interferon on HBV replication (Abstract W 12 ). EASL, Southampton
Watanabe S, Saito S, Yoshikawa A, Shibayama T, Kamimura T, Suziki S, Ischida F (1982) Evaluation of the antiviral effects of adenine arabinoside on chronic HBV infection. Hepatogastroenterology 29: 102
Weimar W, Heijtink RA, Schalm SW et al. (1977) Fibroblast interferon in HBsAg-positive chronic active hepatitis. Lancet II:1282
Weimar W, Heijtink RA, Schalm SW, Schellekens H (1978) Differential effect of exogenous fibroblast and leukocyte interferon in HBsAg chronic hepatitis. Gastroenterology 74: 1150
Weimar W, Heijtink RA, Schalm SW, Schellekens H (1979) Differential effects of fibroblast and leukocyte interferon in HBsAg positive chronic active hepatitis. Eur J Clin Invest 9: 151
Weller ND, Bassendine MF, Murray AR, Summers J, Thomas HC, Sherlock S (1980) HBsAg positive chronic liver disease inhibition of viral replication by highly soluble adenine arabinoside 5’-monophosphate ( ARA-AMP ). Gastroenterology 79: 1129
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Müller, R. (1984). Andere therapeutische Ansätze bei chronisch-aktiver Hepatitis. In: Dölle, W. (eds) Die immunsuppressive Therapie der chronisch-aktiven Hepatitis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-69736-4_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-69736-4_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-13437-4
Online ISBN: 978-3-642-69736-4
eBook Packages: Springer Book Archive